The Taibo® Sildenafil Citrate Orally Disintegrating Tablets (50mg), which is our company's new dosage form and deemed to have passed the consistency evaluation, was recently approved for marketing.
MoreOur existing R&D center in Nanjing will be relocated to a new, larger site in the Nanjing Xingang Economic and Technological Development Zone. The center covers a floor area of 26,668.3 m2 and has a built-up area of nearly 20,000 m2, with a capital i
MoreIn November 2008, C&O participated in the cefditoren licensing meeting organized by Meiji, a leading food and drug company in Japan, held in Tokyo, Japan. C&O has been Meiji’s designated distributor since January 2008 for the sale of its new generati
MoreIn November 2008, C&O launched an exclusive new variety under the trade name of Helixor
MoreThe disposal is in line with the group’s strategy of focusing on the development of high-margin exclusive and private label products.
More
Address5/F, Jihao Building, 1086 Shennan East Road, Luohu District, Shenzhen
Adverse drug reactions / Event feedback hotline025-6816 1304
Adverse drug reactions / Event feedback mailGVP@changao.com
Official WeChat account 
Mobile page